Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
224 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Major Depressive Disorder - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Major Depressive Disorder - Pipeline Review, H1 2016', provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder - The report reviews pipeline therapeutics for Major Depressive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Major Depressive Disorder therapeutics and enlists all their major and minor projects - The report assesses Major Depressive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Major Depressive Disorder Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Major Depressive Disorder Overview 8 Therapeutics Development 9 Pipeline Products for Major Depressive Disorder - Overview 9 Pipeline Products for Major Depressive Disorder - Comparative Analysis 10 Major Depressive Disorder - Therapeutics under Development by Companies 11 Major Depressive Disorder - Therapeutics under Investigation by Universities/Institutes 13 Major Depressive Disorder - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Major Depressive Disorder - Products under Development by Companies 17 Major Depressive Disorder - Products under Investigation by Universities/Institutes 20 Major Depressive Disorder - Companies Involved in Therapeutics Development 21 Aequus Pharmaceuticals Inc. 21 Alkermes Plc 22 Allergan Plc 23 Angelini Group 24 Azevan Pharmaceuticals, Inc. 25 BioCrea GmbH 26 Bristol-Myers Squibb Company 27 Cerecor Inc. 28 e-Therapeutics Plc 29 Eli Lilly and Company 30 F. Hoffmann-La Roche Ltd. 31 GlaxoSmithKline Plc 32 H. Lundbeck A/S 33 Hua Medicine Ltd. 34 Intra-Cellular Therapies, Inc. 35 Johnson & Johnson 36 Lead Discovery Center GmbH 37 Les Laboratoires Servier SAS 38 Luye Pharma Group Ltd. 39 Mapreg S.A.S. 40 Methylation Sciences Inc. 41 miCure Therapeutics Ltd. 42 Mitsubishi Tanabe Pharma Corporation 43 Neuralstem, Inc. 44 nLife Therapeutics, S.L. 45 Otsuka Holdings Co., Ltd. 46 Pherin Pharmaceuticals, Inc. 47 Reviva Pharmaceuticals Inc. 48 Richter Gedeon Nyrt. 49 Saniona AB 50 Sumitomo Dainippon Pharma Co., Ltd. 51 Suven Life Sciences Ltd. 52 Takeda Pharmaceutical Company Limited 53 TRImaran Pharma, Inc. 54 Turing Pharmaceuticals AG 55 VistaGen Therapeutics , Inc. 56 Major Depressive Disorder - Therapeutics Assessment 57 Assessment by Monotherapy Products 57 Assessment by Combination Products 58 Assessment by Target 59 Assessment by Mechanism of Action 62 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 (aripiprazole + sertraline) - Drug Profile 69 (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 70 AAD-2004 - Drug Profile 72 ALKS-7119 - Drug Profile 73 AN-788 - Drug Profile 74 aripiprazole - Drug Profile 75 AV-101 - Drug Profile 76 AVP-786 - Drug Profile 78 basimglurant - Drug Profile 80 BLI-1005 - Drug Profile 82 brexpiprazole - Drug Profile 83 bupropion hydrochloride ER - Drug Profile 86 cariprazine - Drug Profile 87 CB-2202 - Drug Profile 90 CERC-301 - Drug Profile 91 CERC-501 - Drug Profile 92 D-473 - Drug Profile 93 edivoxetine hydrochloride - Drug Profile 94 esketamine hydrochloride - Drug Profile 96 gepirone hydrochloride ER - Drug Profile 99 ITI-007 - Drug Profile 101 JNJ-42847922 - Drug Profile 104 ketamine hydrochloride - Drug Profile 106 lurasidone hydrochloride - Drug Profile 107 LY-03005 - Drug Profile 110 MAP-4343 - Drug Profile 112 MIN-117 - Drug Profile 113 miR-135 - Drug Profile 114 MSI-195 - Drug Profile 115 NLF-NEU - Drug Profile 116 NP-11948 - Drug Profile 118 NRX-1074 - Drug Profile 119 NSI-189 - Drug Profile 120 onabotulinumtoxin A - Drug Profile 122 PH-10 - Drug Profile 125 rapastinel - Drug Profile 126 RP-5063 - Drug Profile 128 S-47445 - Drug Profile 129 sirukumab - Drug Profile 130 Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder - Drug Profile 133 Small Molecule to Target SLC6A15 for Major Depressive Disorder - Drug Profile 134 Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 135 Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile 136 Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 137 SNA-1 - Drug Profile 138 SRX-246 - Drug Profile 139 SUVN-911 - Drug Profile 141 TAK-653 - Drug Profile 142 tramadol hydrochloride - Drug Profile 143 trazodone hydrochloride - Drug Profile 144 vortioxetine hydrobromide - Drug Profile 145 VU-0431316 - Drug Profile 148 Major Depressive Disorder - Recent Pipeline Updates 149 Major Depressive Disorder - Dormant Projects 201 Major Depressive Disorder - Discontinued Products 208 Major Depressive Disorder - Product Development Milestones 211 Featured News & Press Releases 211 Appendix 219 Methodology 219 Coverage 219 Secondary Research 219 Primary Research 219 Expert Panel Validation 219 Contact Us 219 Disclaimer 220
List of Tables
Number of Products under Development for Major Depressive Disorder, H1 2016 13 Number of Products under Development for Major Depressive Disorder - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Development by Companies, H1 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2016 24 Major Depressive Disorder - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 25 Major Depressive Disorder - Pipeline by Alkermes Plc, H1 2016 26 Major Depressive Disorder - Pipeline by Allergan Plc, H1 2016 27 Major Depressive Disorder - Pipeline by Angelini Group, H1 2016 28 Major Depressive Disorder - Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 29 Major Depressive Disorder - Pipeline by BioCrea GmbH, H1 2016 30 Major Depressive Disorder - Pipeline by Bristol-Myers Squibb Company, H1 2016 31 Major Depressive Disorder - Pipeline by Cerecor Inc., H1 2016 32 Major Depressive Disorder - Pipeline by e-Therapeutics Plc, H1 2016 33 Major Depressive Disorder - Pipeline by Eli Lilly and Company, H1 2016 34 Major Depressive Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 35 Major Depressive Disorder - Pipeline by GlaxoSmithKline Plc, H1 2016 36 Major Depressive Disorder - Pipeline by H. Lundbeck A/S, H1 2016 37 Major Depressive Disorder - Pipeline by Hua Medicine Ltd., H1 2016 38 Major Depressive Disorder - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 39 Major Depressive Disorder - Pipeline by Johnson & Johnson, H1 2016 40 Major Depressive Disorder - Pipeline by Lead Discovery Center GmbH, H1 2016 41 Major Depressive Disorder - Pipeline by Les Laboratoires Servier SAS, H1 2016 42 Major Depressive Disorder - Pipeline by Luye Pharma Group Ltd., H1 2016 43 Major Depressive Disorder - Pipeline by Mapreg S.A.S., H1 2016 44 Major Depressive Disorder - Pipeline by Methylation Sciences Inc., H1 2016 45 Major Depressive Disorder - Pipeline by miCure Therapeutics Ltd., H1 2016 46 Major Depressive Disorder - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 47 Major Depressive Disorder - Pipeline by Neuralstem, Inc., H1 2016 48 Major Depressive Disorder - Pipeline by nLife Therapeutics, S.L., H1 2016 49 Major Depressive Disorder - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 50 Major Depressive Disorder - Pipeline by Pherin Pharmaceuticals, Inc., H1 2016 51 Major Depressive Disorder - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 52 Major Depressive Disorder - Pipeline by Richter Gedeon Nyrt., H1 2016 53 Major Depressive Disorder - Pipeline by Saniona AB, H1 2016 54 Major Depressive Disorder - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 55 Major Depressive Disorder - Pipeline by Suven Life Sciences Ltd., H1 2016 56 Major Depressive Disorder - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 57 Major Depressive Disorder - Pipeline by TRImaran Pharma, Inc., H1 2016 58 Major Depressive Disorder - Pipeline by Turing Pharmaceuticals AG , H1 2016 59 Major Depressive Disorder - Pipeline by VistaGen Therapeutics , Inc., H1 2016 60 Assessment by Monotherapy Products, H1 2016 61 Assessment by Combination Products, H1 2016 62 Number of Products by Stage and Target, H1 2016 64 Number of Products by Stage and Mechanism of Action, H1 2016 67 Number of Products by Stage and Route of Administration, H1 2016 70 Number of Products by Stage and Molecule Type, H1 2016 72 Major Depressive Disorder Therapeutics - Recent Pipeline Updates, H1 2016 153 Major Depressive Disorder - Dormant Projects, H1 2016 205 Major Depressive Disorder - Dormant Projects (Contd..1), H1 2016 206 Major Depressive Disorder - Dormant Projects (Contd..2), H1 2016 207 Major Depressive Disorder - Dormant Projects (Contd..3), H1 2016 208 Major Depressive Disorder - Dormant Projects (Contd..4), H1 2016 209 Major Depressive Disorder - Dormant Projects (Contd..5), H1 2016 210 Major Depressive Disorder - Dormant Projects (Contd..6), H1 2016 211 Major Depressive Disorder - Discontinued Products, H1 2016 212 Major Depressive Disorder - Discontinued Products (Contd..1), H1 2016 213 Major Depressive Disorder - Discontinued Products (Contd..2), H1 2016 214
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
